自体荧光测糖尿病微血管病变

2013-04-16 晓东 编译 医学论坛网

     日本学者的一项研究显示,皮肤自体荧光(AF)值可反应1型糖尿病患者既往较长一段时期内的血糖控制情况,或可作为糖尿病微血管并发症的一项生物标志物。研究于2013年4月11日在线发表于《糖尿病护理》杂志。   研究旨在评估日本1型糖尿病患者中皮肤自体荧光(AF)值与既往血糖控制之间的关系,及其与微血管并发症进展之间的相关性。研究纳入241例患者,110例对照组患者。应用AF监测仪评估晚期

  皮肤自体荧光糖尿病微血管病变

  日本学者的一项研究显示,皮肤自体荧光(AF)值可反应1型糖尿病患者既往较长一段时期内的血糖控制情况,或可作为糖尿病微血管并发症的一项生物标志物。研究于2013年4月11日在线发表于《糖尿病护理》杂志。

  研究旨在评估日本1型糖尿病患者中皮肤自体荧光(AF)值与既往血糖控制之间的关系,及其与微血管并发症进展之间的相关性。研究纳入241例患者,110例对照组患者。应用AF监测仪评估晚期糖基化终末产物水平,对患者既往20年内的连续3个月HbA1c水平根据其医疗记录进行评估,计算HbA1c曲线下面积(AUC)。应用多变量回归分析检测糖尿病并发症进展与多变量的相关性。

  结果显示,随着患者视网膜病变与肾脏病变的加重,皮肤AF值亦随之增加。既往15年内患者HbA1c AUC 值与皮肤AF值显著相关(既往5年R = 0.35;既往10年R=0.36;既往15年R = 0.55,p<0.0001)。既往3年、5年、10年及15年患者HbA1c AUC 值与视网膜病变与肾脏病变严重程度显著相关。将HbA1c AUC从独立变量中移除后的多变量分析表明,只有皮肤AF值与肾脏疾病进展独立相关,患者基线年龄、糖尿病发病时的年龄、皮肤AF与视网膜病变独立相关。 

糖尿病相关的拓展阅读:


Skin Autofluorescence Reflects Integration of Past Long-Term Glycemic Control in Patients With Type 1 Diabetes
OBJECTIVE
The aim was to investigate the relationships between skin autofluorescence (AF) and the impact of past glycemic control and microvascular complications in Japanese patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS
Two hundred forty-one patients and 110 controls were enrolled. Advanced glycation end product accumulation was measured with AF reader. Three monthly HbA1c levels during the past 20 years were determined from medical records, and the HbA1c area under the curve (AUC) was calculated. We performed multivariate regression analyses to examine the associations between the severity of diabetes complications and various variables.
RESULTS
Skin AF values increased with increasing the severity of retinopathy (P < 10−11, linear regression analysis) and nephropathy (P < 10−5 for chronic kidney disease stage; P < 10−5 for albuminuria-based stage). HbA1c AUC values over the past 15 years were significantly correlated with skin AF values (past 5 years: R = 0.35, P < 0.0001; past 10 years: R = 0.36, P < 0.0001; past 15 years: R = 0.55, P < 0.0001; past 20 years: R = 0.22, P = 0.13). HbA1c AUC values over the past 3, 5, 10, and 15 years were significantly associated with the severity of both nephropathy and retinopathy. Multivariate analyses in which HbA1c AUC value was removed from the independent variables indicated that only skin AF was independently associated with nephropathy, whereas age at registration, age at onset of diabetes, and skin AF were independently associated with retinopathy.
CONCLUSION
Skin AF reflects past long-term glycemic control and may serve as a surrogate marker for the development of microvascular complications in place of HbA1c AUC value.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1644367, encodeId=92f4164436ea7, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Jun 09 00:02:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707735, encodeId=90211e0773505, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Sun Mar 30 14:02:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365282, encodeId=3b8c13652829c, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391038, encodeId=64a413910386e, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492032, encodeId=1af7149203235, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1644367, encodeId=92f4164436ea7, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Jun 09 00:02:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707735, encodeId=90211e0773505, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Sun Mar 30 14:02:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365282, encodeId=3b8c13652829c, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391038, encodeId=64a413910386e, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492032, encodeId=1af7149203235, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1644367, encodeId=92f4164436ea7, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Jun 09 00:02:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707735, encodeId=90211e0773505, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Sun Mar 30 14:02:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365282, encodeId=3b8c13652829c, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391038, encodeId=64a413910386e, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492032, encodeId=1af7149203235, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=)]
    2013-04-18 mgqwxj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1644367, encodeId=92f4164436ea7, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Jun 09 00:02:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707735, encodeId=90211e0773505, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Sun Mar 30 14:02:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365282, encodeId=3b8c13652829c, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391038, encodeId=64a413910386e, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492032, encodeId=1af7149203235, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1644367, encodeId=92f4164436ea7, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Jun 09 00:02:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707735, encodeId=90211e0773505, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Sun Mar 30 14:02:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365282, encodeId=3b8c13652829c, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391038, encodeId=64a413910386e, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492032, encodeId=1af7149203235, content=<a href='/topic/show?id=a9ff50e92ed' target=_blank style='color:#2F92EE;'>#微血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50792, encryptionId=a9ff50e92ed, topicName=微血管病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a18916252, createdName=longqijun251, createdTime=Thu Apr 18 00:02:00 CST 2013, time=2013-04-18, status=1, ipAttribution=)]

相关资讯

Circulation:1型糖尿病强化降糖体重增加过多升高并发症危险

  近期两项前瞻性研究表明,体重增加过多(DCCT研究中)与持续增长的中心性肥胖、胰岛素抵抗、血脂异常、高血压,以及随访后期(EDIC研究中)更广泛的动脉粥样硬化相关。研究于2012年12月3日在线发表于《循环》(Circulation)杂志。   1型糖尿病(T1DM)的强化降糖治疗可减少糖尿病并发症,但可伴有体重增加过多、中心性肥胖和血脂异常。该前瞻性研究目的在于确定1型糖尿病患者糖尿病治疗

Eur J Endocrinol: 1型糖尿病患者HbA1c水平过高能直接导致抑郁

  瑞典一项研究表明,抑郁与1型糖尿病患者糖化血红蛋白(HbA1c)水平>8.6%独立相关。这种相关性与血糖控制不佳和糖尿病并发症的已知风险因素肥胖和吸烟的重要性具有可比性。抑郁与HbA1c水平>8.6%的相关性在女性当中尤其明显。述情障碍(alexithymia)是一种相对稳定的个性特征,与抑郁相关。今后,在糖尿病患者的护理中,为了使HbA1c达标,应将精神因素与人体测量学(anthropome

“广东省1型糖尿病转化医学研究”中期成果汇报会在成都召开

  “广东省1型糖尿病转化医学研究”中期成果汇报会于2012年12月6日下午在成都世纪城新国际会展中心隆重举行,参与该项目的广东省内16家中心的负责人或代表,以及来自中华医学会的嘉宾出席了汇报会。   汇报会中,项目组组长、中山大学附属第三医院的李津医生介绍了项目概况、目前进展及主要成果。据李医生介绍,“广东省1型糖尿病转化医学研究项目”由广东省科技厅、广东省卫生厅、广东省糖尿病防治研究中心、中

Diabetologia:乳腺癌幸存者更易患糖尿病

       一项新研究表明绝经后乳腺癌幸存者比未患乳腺癌者更容易患糖尿病。此外,乳腺癌和糖尿病之间之间的关系会有所不同,这取决于是否乳腺癌幸存者经历了化疗。相关研究结果发表在2012年12月13日的Diabetologia杂志上。        糖尿病和癌症之间有关联越来越被大家认可。例如,糖尿病妇女患乳腺

JAMA:胰腺大小或可预测1型糖尿病风险

       发表在12月12日JAMA杂志的一项最新研究显示,有1型糖尿病风险的人比无1型糖尿病风险的人有较小的胰腺。有1型糖尿病风险的患者,生成胰岛素的胰腺细胞数量比没有糖尿病风险的群体少。       佛罗里达大学医学部病理学,免疫学和实验室医学教授Martha Campbell-Thompson表示

Eur J Endocrinol:抑郁与1型糖尿病血糖控制不佳相关

  瑞典一项研究表明,抑郁与1型糖尿病患者糖化血红蛋白(HbA1c)水平>8.6%独立相关。这种相关性与血糖控制不佳和糖尿病并发症的已知风险因素肥胖和吸烟的重要性具有可比性。抑郁与HbA1c水平>8.6%的相关性在女性当中尤其明显。述情障碍(alexithymia)是一种相对稳定的个性特征,与抑郁相关。今后,在糖尿病患者的护理中,为了使HbA1c达标,应将精神因素与人体测量学(anthr